SERA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SERA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Sera Prognostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.84 Mil. Sera Prognostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Sera Prognostics's annualized EBITDA for the quarter that ended in Dec. 2024 was $-33.45 Mil. Sera Prognostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -0.03.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Sera Prognostics's Debt-to-EBITDA or its related term are showing as below:
The historical data trend for Sera Prognostics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.51 | - | -0.07 | -0.05 | -0.03 |
Sera Prognostics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.06 | -0.05 | -0.04 | -0.04 | -0.03 |
For the Medical Devices subindustry, Sera Prognostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Sera Prognostics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.838 | + | 0.002) | / | -32.037 | |
= | -0.03 |
Sera Prognostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.838 | + | 0.002) | / | -33.448 | |
= | -0.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2024) EBITDA data.
Sera Prognostics (NAS:SERA) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Sera Prognostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Austin Aerts | officer: Chief Financial Officer | 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109 |
Robert Gardner Harrison | officer: Chief Information Officer | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Zhenya Lindgardt | director | C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109 |
John J. Boniface | officer: Chief Scientific Officer | C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109 |
Mansoor Raza Mirza | director | C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760 |
Benjamin Jackson | officer: General Counsel | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Paul Kearney | officer: Chief Data Officer | 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109 |
Joshua Phillips | director | C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109 |
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Michael R Foley | officer: Chief Medical Officer | C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109 |
Sandra Aj Lawrence | director | C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105 |
Douglas Fisher | officer: Chief Business Officer | 587 PATROL RD, WOODSIDE CA 94062 |
Gregory C Critchfield | director, officer: Chief Executive Officer | 320 WAKARA WAY, SALT LAKE CITY UT 84108 |
Blue Ox Healthcare Partners Sp, Llc | 10 percent owner | 135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022 |
Bxhcp Sp Ii, Llc | 10 percent owner | 135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022 |
From GuruFocus
By PRNewswire • 07-01-2024
By GuruFocus News • 02-15-2025
By PRNewswire • 03-11-2025
By PRNewswire • 03-19-2025
By PRNewswire • 11-06-2024
By PRNewswire • 02-21-2025
By GuruFocus News • 11-06-2024
By PRNewswire • 02-11-2025
By PRNewswire • 07-09-2024
By PRNewswire • 02-10-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.